Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Thérèse Aurran‐Schleinitz(Institut Paoli-Calmettes), David Gottlieb(The University of Sydney), Sophie de Guibert(Centre Hospitalier Universitaire de Rennes), Florence Cymbalista(Hôpital Avicenne), Stephen Larsen(Royal Prince Alfred Hospital), Rosemary Harrup(University of Tasmania), D D Smith(Australasian Leukaemia and Lymphoma Group), Constantine S. Tam(The Alfred Hospital), Jennifer Curnow(Westmead Hospital), Belinda Butcher(UNSW Sydney), Cecily Forsyth(Gosford Hospital), Laurent Voillat, Richard Eek, Marie C. Béné(Centre Hospitalier Universitaire de Nantes), Bernard Drénou(Groupe Hospitalier de la Région de Mulhouse et Sud Alsace), Nicolas Daguindau(Centre Hospitalier Annecy Genevois), Stephen P. Mulligan(Royal North Shore Hospital), Jean Pierre Vilque(Centre Hospitalier Universitaire de Caen Normandie), Andrew Grigg(The Royal Melbourne Hospital), Véronique Leblond(Sorbonne Université), Mourad Tiab(Roche (France)), Gavin Cull(Sir Charles Gairdner Hospital), Caroline Dartigeas(Centre Hospitalier Universitaire de Tours), Rémi Letestu(Hôpital Avicenne)
Cited by 1
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k